Arvinas News

Arvinas Analyst Ratings

BenzingaApr 15 07:24 ET

Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)

TipRanksApr 12 08:29 ET

Arvinas Analyst Ratings

BenzingaApr 12 07:14 ET

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)

TipRanksApr 12 07:10 ET

Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential

TipRanksApr 11 13:05 ET

Arvinas Analyst Ratings

BenzingaMar 25 12:04 ET

Arvinas Holding Company: A Buy Rating on Strong Clinical Pipeline and Promising Trial Outcomes

TipRanksMar 1 00:58 ET

Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion Into Parkinson's Disease Treatment

TipRanksFeb 28 07:36 ET

Arvinas Analyst Ratings

BenzingaFeb 28 07:32 ET

Buy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial Health

TipRanksFeb 28 05:40 ET

Arvinas Holding Company: A Strong Buy on Robust Clinical Data and Strategic Trial Advancements

TipRanksFeb 27 15:46 ET

Arvinas Analyst Ratings

BenzingaFeb 15 11:02 ET

Citi Downgrades Arvinas to Neutral, Cites Valuation

Seeking AlphaFeb 14 15:55 ET

Arvinas Analyst Ratings

BenzingaFeb 14 08:33 ET

Arvinas Holding Company: A Promising Buy Amidst Progressive Drug Development and Strategic Collaborations

TipRanksFeb 8 05:46 ET

Arvinas Analyst Ratings

BenzingaFeb 1 07:03 ET

Goldman Sachs Initiates Buy Rating on Arvinas With a Focus on Innovative Cancer Treatments and Strategic Growth Potential

TipRanksFeb 1 02:25 ET

Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), Pacira Pharmaceuticals (PCRX)

TipRanksJan 7 21:30 ET

Wells Fargo Upgrades Arvinas to Overweight Ahead of Phase 3 Data Readout

Seeking AlphaDec 19, 2023 13:36 ET

Wells Fargo Upgrades Arvinas to Overweight, Announces $63 Price Target

BenzingaDec 19, 2023 07:02 ET